Ptc Therapeutics Stock Short Ratio

PTCT Stock

USD 45.11 0.90 1.96%

PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PTC Therapeutics Company Short Ratio Analysis

PTC Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Short Ratio

Short Interest

Average Trading Volume

More About Short Ratio | All Equity Analysis

Current PTC Therapeutics Short Ratio

6.08 X

Most of PTC Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

PTC Short Ratio Driver Correlations

Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Short Ratio. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Accounts Payable	Long Term Debt	Short Term Investments	Total Liab	Property Plant Equipment	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.24	0.66	0.65	0.67	0.92	0.78	0.27	0.48	-0.87	0.86	0.94	0.51	0.89	-0.85	0.94	0.81	0.24	0.69	0.84	0.93
Total Stockholder Equity	-0.24		0.0	-0.79	0.23	-0.6	-0.57	-0.01	-0.84	0.65	-0.63	-0.35	-0.64	-0.08	0.61	-0.29	-0.7	-0.46	-0.26	-0.08	-0.52
Accounts Payable	0.66	0.0		0.14	0.49	0.54	0.6	0.4	-0.01	-0.56	0.59	0.52	0.21	0.74	-0.6	0.69	0.45	0.2	0.03	0.43	0.62
Long Term Debt	0.65	-0.79	0.14		0.14	0.85	0.65	-0.09	0.95	-0.88	0.84	0.78	0.81	0.49	-0.76	0.61	0.91	0.41	0.7	0.5	0.76
Short Term Investments	0.67	0.23	0.49	0.14		0.46	0.42	0.37	0.03	-0.35	0.27	0.68	0.24	0.57	-0.25	0.58	0.26	0.38	0.46	0.86	0.57
Total Liab	0.92	-0.6	0.54	0.85	0.46		0.87	0.22	0.74	-0.98	0.96	0.91	0.68	0.76	-0.95	0.88	0.95	0.37	0.67	0.72	0.97
Property Plant Equipment	0.78	-0.57	0.6	0.65	0.42	0.87		0.63	0.5	-0.86	0.85	0.71	0.73	0.67	-0.87	0.77	0.76	0.45	0.4	0.51	0.88
Current Deferred Revenue	0.27	-0.01	0.4	-0.09	0.37	0.22	0.63		-0.24	-0.16	0.17	0.1	0.3	0.23	-0.26	0.25	-0.01	0.27	-0.07	0.11	0.28
Net Debt	0.48	-0.84	-0.01	0.95	0.03	0.74	0.5	-0.24		-0.76	0.72	0.65	0.68	0.29	-0.65	0.45	0.83	0.45	0.6	0.42	0.64
Retained Earnings	-0.87	0.65	-0.56	-0.88	-0.35	-0.98	-0.86	-0.16	-0.76		-0.99	-0.88	-0.73	-0.78	0.95	-0.88	-0.97	-0.4	-0.63	-0.63	-0.94
Net Receivables	0.86	-0.63	0.59	0.84	0.27	0.96	0.85	0.17	0.72	-0.99		0.83	0.67	0.78	-0.98	0.86	0.95	0.3	0.56	0.56	0.91
Total Current Assets	0.94	-0.35	0.52	0.78	0.68	0.91	0.71	0.1	0.65	-0.88	0.83		0.65	0.82	-0.77	0.87	0.85	0.39	0.77	0.88	0.92
Short Term Debt	0.51	-0.64	0.21	0.81	0.24	0.68	0.73	0.3	0.68	-0.73	0.67	0.65		0.46	-0.57	0.5	0.66	0.56	0.5	0.34	0.61
Common Stock	0.89	-0.08	0.74	0.49	0.57	0.76	0.67	0.23	0.29	-0.78	0.78	0.82	0.46		-0.75	0.94	0.67	0.23	0.59	0.67	0.78
Net Tangible Assets	-0.85	0.61	-0.6	-0.76	-0.25	-0.95	-0.87	-0.26	-0.65	0.95	-0.98	-0.77	-0.57	-0.75		-0.86	-0.91	-0.24	-0.51	-0.52	-0.9
Capital Surpluse	0.94	-0.29	0.69	0.61	0.58	0.88	0.77	0.25	0.45	-0.88	0.86	0.87	0.5	0.94	-0.86		0.8	0.33	0.69	0.77	0.91
Long Term Debt Total	0.81	-0.7	0.45	0.91	0.26	0.95	0.76	-0.01	0.83	-0.97	0.95	0.85	0.66	0.67	-0.91	0.8		0.32	0.63	0.6	0.91
Short Long Term Debt	0.24	-0.46	0.2	0.41	0.38	0.37	0.45	0.27	0.45	-0.4	0.3	0.39	0.56	0.23	-0.24	0.33	0.32		0.31	0.41	0.43
Net Invested Capital	0.69	-0.26	0.03	0.7	0.46	0.67	0.4	-0.07	0.6	-0.63	0.56	0.77	0.5	0.59	-0.51	0.69	0.63	0.31		0.77	0.64
Net Working Capital	0.84	-0.08	0.43	0.5	0.86	0.72	0.51	0.11	0.42	-0.63	0.56	0.88	0.34	0.67	-0.52	0.77	0.6	0.41	0.77		0.79
Capital Stock	0.93	-0.52	0.62	0.76	0.57	0.97	0.88	0.28	0.64	-0.94	0.91	0.92	0.61	0.78	-0.9	0.91	0.91	0.43	0.64	0.79

Click cells to compare fundamentals

The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.

Competition

Predict PTC Therapeutics

PTC Price To Sales Ratio

Price To Sales Ratio

2.09

At this time, PTC Therapeutics' Price To Sales Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, PTC Therapeutics has a Short Ratio of 6.08 times. This is 55.9% higher than that of the Biotechnology sector and 17.95% lower than that of the Health Care industry. The short ratio for all United States stocks is 52.0% lower than that of the firm.

PTC Short Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.

PTC Therapeutics is currently under evaluation in short ratio category among its peers.

PTC Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	2.8B	4.0B	2.8B	2.7B	2.1B	1.3B
Enterprise Value	2.5B	4.2B	2.5B	3.0B	3.7B	3.9B

PTC Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

PTC Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in PTC Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of PTC Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PTC Therapeutics' value.

		Shares
Jacobs Levy Equity Management, Inc.	2024-09-30	1.5 M
D. E. Shaw & Co Lp	2024-09-30	1.4 M
Franklin Resources Inc	2024-09-30	1.4 M
Blackstone Inc	2024-09-30	1.1 M
Fmr Inc	2024-09-30	1.1 M
Goldman Sachs Group Inc	2024-06-30	791.2 K
Charles Schwab Investment Management Inc	2024-09-30	706.7 K
Tang Capital Management Llc	2024-09-30	700 K
Nuveen Asset Management, Llc	2024-06-30	686.5 K
Vanguard Group Inc	2024-09-30	9.1 M
Wellington Management Company Llp	2024-06-30	8.2 M

PTC Fundamentals

	Return On Equity	-77.4
	Return On Asset	-0.0515
	Profit Margin	(0.50) %
	Operating Margin	(0.26) %
	Current Valuation	2.87 B
	Shares Outstanding	77.13 M
	Shares Owned By Insiders	2.34 %
	Shares Owned By Institutions	97.66 %
	Number Of Shares Shorted	4.67 M
	Price To Earning	(5.67) X
	Price To Book	1,743 X
	Price To Sales	3.86 X
	Revenue	937.82 M
	Gross Profit	2.63 M
	EBITDA	(330.34 M)
	Net Income	(626.6 M)
	Cash And Equivalents	288.43 M
	Cash Per Share	4.01 X
	Total Debt	2.23 B
	Current Ratio	1.23 X
	Book Value Per Share	(13.70) X
	Cash Flow From Operations	(158.42 M)
	Short Ratio	6.08 X
	Earnings Per Share	(5.94) X
	Price To Earnings To Growth	0.81 X
	Target Price	46.14
	Number Of Employees	988
	Beta	0.63
	Market Capitalization	3.48 B
	Total Asset	1.9 B
	Retained Earnings	(3.28 B)
	Working Capital	615.53 M
	Current Asset	355.95 M
	Current Liabilities	45.39 M
	Net Asset	1.9 B

About PTC Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC